Health News

A New Multiple Myeloma Treatment
Another treatment for multiple myeloma just got an OK from the FDA.
FDA Approves New Multiple Myeloma Rx
Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.
New Indication for Pradaxa
RIDGEFIELD, Conn., November 23, 2015 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Pradaxa® (dabigatran etexilate mesylate) for the prophylaxis of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have undergone hip replacement surgery.
New Recommendations for Hemophilia Patients
The National Hemophilia Foundation (NHF) recently issued a new recommendation on inhibitor testing for patients with hemophilia A and B.
New Multiple Myeloma Rx Gets Go-Ahead
A new FDA approval could give another option to multiple myeloma patients who haven't had luck with past treatments. {C}
Ninlaro Approved for Multiple Myeloma
Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy.
An Extra Benefit for Sickle Cell Rx
A drug commonly used to treat sickle cell disease (SCD) may wind up helping patients in more ways than one.
A Shot Against Multiple Myeloma
For multiple myeloma patients who haven't responded to past treatments, a newly approved medication could provide hope.
New Rx for Multiple Myeloma
Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments.
Modified Hemophilia Rx Approved
The U.S. Food and Drug Administration today approved Adynovate, Antihemophilic Factor (Recombinant), PEGylated for use in adults and adolescents, aged 12 years and older, who have Hemophilia A.